PITTSBURGH, July 11, 2017 /PRNewswire/ — Carmell Therapeutics, a biotechnology company focused on developing and commercializing regenerative medicine technologies, announced today that on June 30, 2017 it closed a $4M Series B financing that will be used to advance its first product candidate, Bone Healing Accelerant, to phase III clinical development.  Carmell received strong support from current investors, […]

Share on LinkedInShare on FacebookShare on Google+Pin on PinterestEmail this to someone